1[1]Weiller E,Bisserbe Jc,Maier W,et al.Prevalence and recognition of anxiety syndromes in five European primary care setting:a report from the WHO study on psychological problems in general health care.Br J Psychiatry,1998,173(Suppl 34):8～23.
2[2]Ballenger JC.Clinical guidelines for establishing remission in patients with depression and anxiety.J Clin Psychiatry,1999,60(Suppl 22):29～34.
3[3]Rickels K,Downing R,Schweizer E,et al.Antidepressants for the treatment of generalized anxiety disorder:a placebo-controlled comparison of imipramine,trazodne,and diazepam.Arch Gen Psychiatry,1993,50(6):884～895.
4[4]Salzman C,Miyawakj EK,le Bars P,et al.Neurobiologic basis of anxiety and its treatment.Harv Rev Psychiatry,1993,29(1):197～206.
5[5]Blackweu B.Adverse effects of antidepressant drugs,Pt 1:monoamine oxidase inhibitors and tricyclics.Drugs,1981,21(2):201～219.
6[6]Allgulander C,Cloniger CR,Przybeck TR,et al.Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder.Psychopharmacol Bull,1998,34(1):165～166.
7[7]Meoni P,Hackett D.Characterization of the longitudinal course of long-term venlafaxine ER treatment of GAD.Presented at the 22nd annual meeting of the collegium internationale.Neuro-Psychopharmacologicum,July 9-132000,Brussels,Belgium.
8[8]Hedges DW,Reimherr FW,Strong RE,et al.An open trial of nefazodone in adult patients with generalized anxiety disorder.Psychopharmacol Bull,1996,32(5):671～676.
